210
Views
6
CrossRef citations to date
0
Altmetric
Original Article

Alpha 1-antitrypsin for treating ventilator-associated lung injury in acute respiratory distress syndrome rats

ORCID Icon, , , &
Pages 209-219 | Received 08 Dec 2018, Accepted 09 Jul 2019, Published online: 26 Jul 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Douweh Leyla Gbian & Abdelwahab Omri. (2021) Current and novel therapeutic strategies for the management of cystic fibrosis. Expert Opinion on Drug Delivery 18:5, pages 535-552.
Read now

Articles from other publishers (5)

Gaihua He, Weihua Yu, Hongwei Li, Jiangzheng Liu, Yongmei Tu, Deqin Kong, Zi Long, Rui Liu, Jie Peng, Zhao Wang, Penghui Liu, Chunxu Hai, Wenjun Yan & Wenli Li. (2023) Alpha-1 antitrypsin protects against phosgene-induced acute lung injury by activating the ID1-dependent anti-inflammatory response. European Journal of Pharmacology 957, pages 176017.
Crossref
Xiyuan Bai, Tony Schountz, Ashley M. Buckle, Janet L. Talbert, Robert A. Sandhaus & Edward D. Chan. (2023) Alpha-1-antitrypsin antagonizes COVID-19: a review of the epidemiology, molecular mechanisms, and clinical evidence. Biochemical Society Transactions 51:3, pages 1361-1375.
Crossref
Jordan R. Yaron, Liqiang Zhang, Qiuyun Guo, Shelley E. Haydel & Alexandra R. Lucas. (2021) Fibrinolytic Serine Proteases, Therapeutic Serpins and Inflammation: Fire Dancers and Firestorms. Frontiers in Cardiovascular Medicine 8.
Crossref
Xiyuan Bai, Joseph Hippensteel, Alida Leavitt, James P. Maloney, David Beckham, Cindy Garcia, Qing Li, Brian M. Freed, Diane Ordway, Robert A. Sandhaus & Edward D. Chan. (2021) Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19. Medical Hypotheses 146, pages 110394.
Crossref
Shahd Horie, Bairbre McNicholas, Emanuele Rezoagli, Tài Pham, Ger Curley, Danny McAuley, Cecilia O’Kane, Alistair Nichol, Claudia dos Santos, Patricia R. M. Rocco, Giacomo Bellani & John G. Laffey. (2020) Emerging pharmacological therapies for ARDS: COVID-19 and beyond. Intensive Care Medicine 46:12, pages 2265-2283.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.